Skip to main content

Advertisement

SpringerLink
Log in

Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?

  • Short Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the intensity and the duration of acneiform skin rash in young and elderly patients, to define a possible relationship between age and skin rash. We retrospectively analyzed all consecutive patients with advanced NSCLC who developed acneiform skin rash during erlotinib treatment at our Clinical Oncology Unit from June 2006 to May 2011. We divided the general case study into two subgroups: young and elderly patients (≥65 years) and we compared clinical, pathological and therapeutical characteristics of both subgroups. Among 25 patients affected by advanced NSCLC treated with erlotinib during the reference period, 19 patients (76.0 %) developed acneiform skin rash. Fourteen (73.7 %) of 19 patients were elderly. The majority of elderly patients has developed acneiform skin rash (82.4 vs 62.5 %). In addition, in elderly patients, acneiform skin rash has a higher intensity (for mild rash 7.1 vs 20.0 %, for moderate rash 57.1 vs 60.0 %, for severe rash 35.7 vs 20.0 %) and longer duration, especially for mild and moderate rash (for mild rash 154 vs 40 days, for moderate rash 120 vs 76 days, for severe rash 31 vs 85 days). The univariate analysis showed no statistical significant difference in OS between young and elderly patients (p = 0.191), such as age, does not seem to influence the appearance (p = 0.386), duration (p = 0.455) and grade of acneiform skin rash (p = 0.765). In conclusion, we can affirm that age is an insufficient predictor of acneiform skin rash during erlotinib treatment in advanced NSCLC and does not seem to statistically influence the appearance, duration and grade of skin rash.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Binder D, Buckendahl AC, Hübner RH et al (2012) Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker. Med Oncol 29:193–198

    Article  PubMed  CAS  Google Scholar 

  2. Drobnienė M, Cicėnienė A, Zelvienė TP et al (2011) Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy. Medicina (Kaunas) 47:520–525

    Google Scholar 

  3. Faehling M, Eckert R, Kuom S et al (2010) Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 78:249–258

    Article  PubMed  CAS  Google Scholar 

  4. John T, Liu G, Tsao MS (2009) Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28:14–23

    Article  Google Scholar 

  5. Kobayashi T, Koizumi T, Agatsuma T et al (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69:1241–1246

    Article  PubMed  CAS  Google Scholar 

  6. Lacouture ME, Melosky BL (2007) Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective. Skin Therapy Lett 12:1–5

    PubMed  CAS  Google Scholar 

  7. Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107–119

    Article  PubMed  Google Scholar 

  8. Liu W, Wu X, Zhang W et al (2007) Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res 13:6788–6795

    Article  PubMed  CAS  Google Scholar 

  9. Lynch TJ Jr, Kim ES, Eaby B et al (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621

    Article  PubMed  CAS  Google Scholar 

  10. Mazzoni F, Rotella V, Pratesi N et al (2011) From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy. Tumori 97:160–165

    PubMed  CAS  Google Scholar 

  11. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  12. Ocvirk J, Rebersek M (2008) Management of cutaneous side effects of cetuximab therapy with vitamin K1 crème. Radiol Oncol 42:2152–2154

    Article  Google Scholar 

  13. Pallis AG, Fortpied C, Wedding U et al (2010) EORTC elderly task force position paper approach to the older cancer patient. Eur J Cancer 46:1502–1513

    Article  PubMed  CAS  Google Scholar 

  14. Pander J, Guchelaar HJ, Gelderblom H (2010) Pharmacogenetics of small-molecule tyrosine kinase inhibitors: optimizing the magic bullet. Curr Opin Mol Ther 12:654–661

    PubMed  CAS  Google Scholar 

  15. Pérez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 17:23–28

    Google Scholar 

  16. Repetto L, Fratino L, Audisio RA et al (2002) Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J Clin Oncol 20:494–502

    Article  PubMed  Google Scholar 

  17. Sasaki H, Okuda K, Shimizu S et al (2009) EGFR R497K polymorphism is a favourable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol 135:31331–31338

    Article  Google Scholar 

  18. Segaert S, Tabernero J, Chosidow O et al (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599–606

    Article  PubMed  Google Scholar 

  19. Shepherd FA, Rodriques Pereira JR, Tan EH et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  PubMed  CAS  Google Scholar 

  20. Thatcher N, Nicolson M, Groves RW et al (2009) Expert consensus on the management of erlotinib-associated cutaneous toxicity in the U.K. Oncologist 14:840–847

    PubMed  CAS  Google Scholar 

  21. Uhm JE, Park BB, Ahn MJ et al (2009) Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer: a multicenter trial by the Korean cancer study group. J Thorac Oncol 4:1136–1143

    Article  PubMed  Google Scholar 

  22. Wollenberg A, Moosmann N, Klein E et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790–792

    Article  PubMed  Google Scholar 

  23. Yoshioka H, Hotta K, Kiura K et al (2010) A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama lung cancer study group trial 0705. J Thorac Oncol 5:99–104

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Palliative Care Unit, Mater Salutis Hospital, ULSS 21, Via Gianella 1, 37045, Legnago (Verona), Italy

    Jacopo Giuliani

  2. Clinical Oncology Unit, St. Anna University-Hospital, Ferrara, Italy

    Marina Marzola

Authors
  1. Jacopo Giuliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina Marzola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacopo Giuliani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giuliani, J., Marzola, M. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?. Arch Dermatol Res 305, 653–658 (2013). https://doi.org/10.1007/s00403-013-1345-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-013-1345-6

Keywords

Search

Navigation